Page 20 - Boxed Warning News Today

STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutic...

The FDA has approved the first generics of Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets.

The Food and Drug Administration has approved Tyruko (natalizumab-sztn), a biosimilar to Tysabri (natalizumab).

The FDA has approved Veopoz (pozelimab-bbfg) for the treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease.

Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have recei

The treatment is the first of its kind to be FDA-approved to treat CHAPLE disease.

First positive Phase 3 results for WELIREG from LITESPARK-005 showed statistically significant improvements in PFS versus everolimus in these patientsRAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from LITESPARK-005,...

INDIANA - The FDA has approved Veopoz (pozelimab-bbfg) injection, a complement inhibitor, for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease. Veopoz is the first FDA-approved treatment for C ...

/PRNewswire/ -- Altruix, a leading provider of behavioral health pharmacy solutions, announced today that it has been selected as a limited distribution...

The FDA has approved Sohonos™ (palovarotene) for patients with fibrodysplasia ossificans progressiva.